Perrigo Company plc announced that it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Zovirax® Cream, 5% (acyclovir cream, 5%) developed in collaboration with Sol-Gel Technologies Ltd. The Company anticipates launching the product this month. Annual market sales for the twelve months ending December 2018 were approximately $92 million as measured by IQVIA™.